FDA EUA legacy Leverage Cellex’s FDA Emergency Use Authorization for rapid diagnostics to position advanced POC serology capabilities to hospitals and clinics seeking proven crisis-response tools and regulatory-compliant testing solutions.

Global expansion Cellex is expanding manufacturing and presence internationally, including a facility in Cologne, Germany, presenting opportunities to partner on regional supply chains, regulatory support, and European distribution of diagnostics and cell therapy-related products.

Biotech integration Capitalize on Cellex’s work across biotechnology instruments, assays, and cell manufacturing to offer integrated solutions that span rapid diagnostics, sample handling, and advanced therapy production for research institutions and healthcare providers.

Public–private partnerships Leverage past co-development efforts with partners (for example Gauss) to propose co-funded pilot programs, joint development of next-gen detection kits, and scalable software-enabled testing workflows suitable for clinics and mobile testing sites.

Regulatory and quality emphasis Position as a reliable supplier for regulated diagnostics and biomanufacturing components by highlighting experience with HIPAA-compliant apps, EUA history, and quality-minded manufacturing capabilities to win bids from hospital networks and government programs.